PDF
(130KB)
i
This article has been updated.
A Correction to this article was published on .
i
The Original Article was published on
i
The Original Article was published on
i
This article has been updated
i
This article was retracted on
i
This article has been updated
Abstract
Macromolecular drugs including peptides, proteins, antibodies, polysaccharides and nucleic acids have been widely used for therapy of major diseases such as carcinoma and AIDS as well as cardiovascular and neurodegenerative disorders among other medical conditions. Due to their unmatched properties of high selectivity and efficiency, macromolecular drugs have been recognized as the drug-of-choice of the future. Since worldwide progress on macromolecular therapeutics still remains in the infant stage and is therefore wide open for equal-ground competition, R&D related to macromolecular drugs should be considered as the main point of focus in China in setting up its strategic plans in pharmaceutical development. In this article, research strategies and drug delivery approaches that should be adopted to enhance the therapeutic effects of macromolecular drugs are reviewed. In addition, comments concerning how to implement such strategies to excel from competition in this challenging research field, such as the design of innovative and highly effective delivery systems of macromolecular drugs with self-owned intellectual property rights, are provided.
Keywords
31\2d\7b\87\hcm0000109039.html
Cite this article
Download citation ▾
Huining HE, Victor C. YANG, Weibing DONG, Junbo GONG, Jingkang WANG,.
Developing macromolecular therapeutics: the future
drug-of-choice.
Front. Chem. Sci. Eng., 2010, 4 (1) : 10-17 DOI:10.1007/s11705-009-0291-5
CHANGE HISTORY
A Correction to this paper has been published:
https://doi.org
The Retraction Note was updated to reflect reception of statements of disagreement from all authors.
This article has been retracted.Please see the Retraction Notice for more detail:
https://doi.org